Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering By: MarketWatch July 28, 2023 at 08:13 AM EDT Biogen's all-cash deal is a rare-disease play. Read More >> Related Stocks: Biogen Idec Reata Pharma S&P Biotech SPDR
